How to access and process FDA drug approval packages for use in research

BMJ (Online)

Volumn 347, Issue , 2013, Pages

  Turner, Erick H ^a,b,c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; DESVENLAFAXINE; GENERIC DRUG; VENLAFAXINE; VILAZODONE;

ACCESS TO INFORMATION; ARTICLE; BIPOLAR MANIA; DRUG APPROVAL; DRUG INDICATION; DRUG INFORMATION; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENERALIZED ANXIETY DISORDER; HUMAN; INFORMATION RETRIEVAL; INFORMATION SERVICE; INTERNET; MAJOR DEPRESSION; PANIC; PRIORITY JOURNAL; SOCIAL PHOBIA;

ACCESS TO INFORMATION; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; INTERNET; RESEARCH DESIGN; REVIEW LITERATURE AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84888778352     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f5992     Document Type: Article

References (26)

1. McDonagh MS, Peterson K, Balshem H, Helfand M. US Food and Drug Administration documents can provide unpublished evidence relevant to systematic reviews. J Clin Epidemiol 2013 July 12 [Epub ahead of print].
2. Chan A-W. Out of sight but not out of mind: how to search for unpublished clinical trial evidence. BMJ 2011;344:d8013.
3. Doshi P, Jefferson T. The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer. JAMA Intern Med 2013;173:380-2.
4. PLoS Medicine Editors. Getting more generous with the truth: clinical trial reporting in 2013 and beyond. PLoS Med 2013;10:e1001379.
5. Steinbrook R. The European Medicines Agency and the brave new world of access to clinical trial data. Arch Intern Med 2012;1-2.
6. Committee on Government Reform, House of Representatives, 109th Congress, et al. A citizen's guide on using the Freedom of Information Act and the Privacy Act of 1974 to request government records. US Government Printing Office, 2005.
7. Turner EH. A taxpayer-funded clinical trials registry and results database. PLoS Med 2004;1:e60.
8. MacLean CH, Morton SC, Ofman JJ, Roth EA, Shekelle PG. How useful are unpublished data from the Food and Drug Administration in meta-analysis? J Clin Epidemiol 2003;56:44-51.
9. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
10. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 2008;5:e217; discussion e217.
11. Schwartz LM, Woloshin S. Lost in transmission-FDA drug information that never reaches clinicians. N Engl J Med 2009;361:1717-20.
12. Schwartz LM, Woloshin S. How the FDA forgot the evidence: the case of donepezil 23 mg. BMJ 2012;344:e1086.
13. Turner EH, Knoepflmacher D, Shapley L. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. PLoS Med 2012;9:e1001189.
14. Schroll JB, Bero L, Gotzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ 2013;346:f2231-1.
15. Bennett DA, Jull A. FDA: untapped source of unpublished trials. Lancet 2003;361:1402-3.
16. Lurie P, Zieve A. Sometimes the silence can be like the thunder: access to pharmaceutical data at the FDA. Law & Contemp Probs 2006;68:85.
17. O'Connor AB. The need for improved access to FDA reviews. JAMA 2009;302:191-3.
18. Cook GE, Madden MM. The significance of information posted on the US Food and Drug Administration's website. J Manag Care Pharm 2012;19:72-3.
19. Marchand HC, Ros BJ, Fine AM, Kremzner ME. The US Food and Drug Administration: drug information resource for formulary recommendations. J Manag Care Pharm 2012;18:713-8.
20. Navarro RP. Rediscovering FDA websites. J Manag Care Pharm 2012;18:719-20.
21. Ohmer J, Miller JW, Sasich LD. Accessing FDA approval packages and briefing documents. Ann Pharmacotherapy 2007;41:2071-2.
22. Food and Drug Administration. Executive summary of the Food and Drug Administration's consumer roundtable on consumer protection priorities. 2000.
23. Turner EH. Posting FDA new drug application reviews. JAMA 2007;298:863-4.
24. Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, Thompson MJ. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012;1:CD008965.
25. Zarin DA, Tse T. Moving toward transparency of clinical trials. Science 2008;319:1340-2.
26. Schroll J. Deaths in trials should always be reported. BMJ 2013;347:f4219.